SCHEMBL4855183

SCHEMBL4855183

CCOC(=O)COc1ccc(NC(=O)OC(C)(C)C)cc1C

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.51
PPARG P37231 1/20 0.50
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA9 Q16790 1/20 0.46
MAPT P10636 3/20 0.44
MAPK1 P28482 1/20 0.44
NLRP3 Q96P20 3/20 0.43
VDR P11473 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 1/20 0.43
IDH1 O75874 1/20 0.42
AAK1 Q2M2I8 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1549735 0.91 HTT (0.47) PPARGCA12CA1CA9MAPT
SCHEMBL4851624 0.88 ALDH1A1 (0.55) PPARGMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL4851453 0.88 RORC (0.54) PPARGMAPTNLRP3SMN1; SMN2ALDH1A1
SCHEMBL4854202 0.88 FFAR1 (0.47) PPARGCA12CA1CA9MAPT
SCHEMBL8325689 0.87 CA12 (0.48) PPARGCA12CA1CA9ALDH1A1
SCHEMBL4851692 0.86 S1PR1 (0.45) PPARGCA12CA1CA9MAPT
SCHEMBL4861306 0.85 ESR1 (0.49) ESR1PPARGMAPTMAPK1VDR
SCHEMBL8477824 0.84 ALDH1A1 (0.61) MAPTMAPK1SMN1; SMN2ALDH1A1MEN1
SCHEMBL4853553 0.83 NLRP3 (0.45) ESR1PPARGCA12CA1CA9
SCHEMBL4856473 0.82 EPHX2 (0.54) PPARGMAPTMAPK1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345067-B2 Aniline derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2008-03-18 US disclosed
EP-1636198-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-03-22 EP disclosed
WO-2004111020-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-12-23 WO disclosed
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-12-09 US disclosed
US-5854245-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1998-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals PPARA, PPARD, PPARG ESR1 1044/4885PPARG 3/4885CA12 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.